Ron K. Labrum brings extensive experience leading Fortune 100 healthcare companies

Bloomington, Ind., (Sept. 14, 2011) – A Chicago-based executive with more than 29 years of experience working with Fortune 100 leaders in the healthcare industry has been named to the Board of Directors of ProCure Treatment Centers, Inc. (ProCure). Ron K. Labrum, 55, will join a board comprising of medical professionals to advance ProCure’s mission to improve the lives of patients with cancer by providing access to proton therapy, an alternative to standard radiation for many tumors. 
 
Labrum currently serves as president and chief executive officer of Fenwal, Inc., a global leader in products and technologies that support and improve blood collection, processing and transfusion medicine. Prior to working with Fenwal, Labrum served in leadership roles with Cardinal Health, Allegiance Corporation, Baxter International and American Hospital Supply Corporation.
 
“Ron has a very extensive track record in leadership roles and has been directing his company into a phase of rapid growth,” said Hadley Ford, chief executive officer of ProCure. “His skills will complement those of others on our board as we continue to grow our network of proton therapy centers, with our third Center opening in Somerset, New Jersey in early 2012. We welcome his expertise.”
 
“I am delighted to be involved with ProCure as we strive to make proton therapy more readily available to cancer patients here and around the world,” said Labrum. “We all feel the impact of cancer in some way and I look forward to working to ensure patients have access to this significant advance in treatment. I’ve worked in healthcare for all of my professional life and know what an important difference an improved technology can have.”

Labrum, who lives in Libertyville, serves on the board of trustees for the National Blood Foundation and is a director of PDS Biotechnology, a drug-development company; and of BCU, a national credit union.  He serves on the executive board of the Northeast Illinois Council of the Boy Scouts of America and has volunteered with the Scouts since 1995. He holds a bachelor’s degree in business administration from Utah State University.
ProCure, founded in 2005, is the market leader in developing and operating proton therapy centers and a network of centers, with two open and treating patients, two under construction and others in development.
 

New board member’s experience in oncology services supports ProCure’s mission

Bloomington, Ind., (Sept. 14, 2011) – ProCure Treatment Centers, Inc. (ProCure) today announced that seasoned healthcare executive David S. Chernow has been named to its Board of Directors. Chernow, 54, has more than 20 years of experience in the healthcare sector steering oncology services organizations.

Chernow currently serves as president and chief development and strategy officer for Select Medical, a leading provider of specialized healthcare in long-term acute care and inpatient and outpatient rehabilitation settings. He previously served as president and chief strategy officer with Select Medical, and has held leadership roles with Oncure Medical Corp., Junior Achievement Worldwide, and US Oncology. In 1992, he also co-founded and subsequently led American Oncology Resources until it merged with Physician Reliance Network, Inc.

“David has spent his entire career helping build exceptional healthcare organizations,” said Hadley Ford, chief executive officer of ProCure. “With centers open in Chicago and Oklahoma City, one about to open in New Jersey and others in development, we will benefit from David’s expertise as we continue to expand this already robust network. His extensive background in oncology is a welcome addition to the board.”

“Improving cancer care is my passion,” said Chernow, a 30-year cancer survivor. “I’m fortunate and I know it. I had testicular cancer, one of the cancers for which they developed a cure. As a result, I am alive today. And with the evolving state of proton therapy, more lives will be saved and cancer care will be greatly enhanced. I am therefore committed to helping an already innovative organization like ProCure to further improve its quality of care. Working together, we can enhance cancer care in this country.”

Chernow previously served on the board of the National Coalition of Cancer Survivorship and currently serves on the Moffitt Cancer Center Advisory Board, Tampa, Fla. He holds a bachelor’s degree from the University of California at Los Angeles, and a law degree from Pepperdine University, Malibu, Cal. Chernow and his family live in Mechanicsburg, Penn.

ProCure, founded in 2005, is the market leader in developing and operating proton therapy centers and a network of centers, with two open and treating patients, two under construction and others in development.

Proton therapy is an advanced form of radiation treatment and an important alternative to standard X-ray radiation for many patients with cancer and for some non-cancerous tumors. Currently available at only nine centers in the United States, proton therapy has been shown to be beneficial in the treatment of a broad range of tumor types including brain, central nervous system, gastrointestinal, head and neck, lung and prostate as well as sarcomas and many pediatric cancers.

The precision of proton therapy makes it especially effective for treating children and adults with anatomically complex tumors, such as those at the base of the skull and along the spinal cord. Patients who receive proton therapy generally experience fewer side effects compared to those who undergo traditional X-ray radiation treatment.

###

ABOUT PROCURE

ProCure Treatment Centers, Inc. is a privately held health care company dedicated to improving the lives of patients with cancer by increasing access to proton therapy. The company was founded in 2005 in Bloomington, Ind., and is the first to develop a network of proton therapy centers in cities across the United States. The ProCure Proton Therapy Center in Oklahoma City opened in July 2009 and the CDH Proton Center, A ProCure Center, located in Warrenville, Ill, opened in October 2010. ProCure’s third and fourth centers are under construction in Somerset, N.J. (opening in 2012), and Seattle, Wash. (opening in 2013); and others are in development. ProCure provides management leadership and a comprehensive approach for the design, construction, financing, staffing, training and day-to-day operations of proton therapy centers.  ProCure’s solution reduces the time, cost and effort necessary to build and operate a facility. ProCure is advancing proton therapy by collaborating with radiation oncology practices and hospitals to develop centers through innovation and improvements in technology, and by providing training at the world’s only educational facility specializing in proton therapy.  For more information, visit procure.com.